Ocular Therapeutix (NSDQ:OCUL) revealed yesterday that it plans to cut 26 jobs across the Bedford, Mass.-based company – about 19% of its workforce.
The effort to reorganize comes just weeks after the FDA rejected Ocular’s resubmitted new drug application for its hydrogel plug, Dextenza.
Get the full story at our sister site, Drug Delivery Business News.
The post Ocular Therapeutix slashes workforce following FDA rejection appeared first on MassDevice.
from MassDevice http://ift.tt/2vofyVH
Cap comentari:
Publica un comentari a l'entrada